HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
SHANGHAI and CLINTON, N.J., May 24, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the appointment of gene therapy industry veteran, Alvin Luk, Ph.D., M.B.A., C.C.R.A., as Co-Founder, Member of the Board of Directors, and Chief Executive Officer.
- SHANGHAI and CLINTON, N.J., May 24, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the appointment of gene therapy industry veteran, Alvin Luk, Ph.D., M.B.A., C.C.R.A., as Co-Founder, Member of the Board of Directors, and Chief Executive Officer.
- My team and I look forward to working closely with Alvin to ensure continuity, build on the progress HuidaGene made, and deliver value to our stakeholders."
- We warmly welcome Alvin to join the HuidaGene team and provide direct guidance for the ongoing IITs, IND submissions, and international collaborations.
- For more information about Dr. Luk, please see recent news of 'HuidaGene Appoints New Members to the Scientific Advisory Board' ( https://www.prnewswire.com/news-releases/huidagene-appoints-new-members-... ).